**DRAFT—Exception to Embargo Policy Letter to the American Diabetes Association**

To: American Diabetes Association

This letter is to confirm our disclosure obligations under applicable federal securities laws with regard to information included in abstract *[enter presentation number], [enter abstract title]*, submitted for presentation at the American Diabetes Association’s [enter meeting year] Scientific Sessions.

On JuneXX, 20XX, XYZ Corporation will present its second quarter results in a press release and investor presentation. It is my opinion that XYZ Corporation would not meet its obligations under Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5(b) promulgated there under without, at a minimum, disclosing a summary of the topline results (overall response rate, median duration of response, and safety information) from *[enter title]* in connection with the initial public disclosure of the results of the study.

The co-authors of this abstract have been notified of our intent to issue a press release (included) on June XX, 20XX. Please do not hesitate to contact me if you have any questions about the statements above.

Sincerely,

**John Smith, Esq.**

**General Counsel**

**Company**

**Contact information**